Article Text

Download PDFPDF
554 Where does the prognosis of grade 2 endometrioid endometrial cancer stands in the spectrum between low and high grade endometrioid tumours?
  1. Andreas Zouridis1,
  2. Ammara Kashif1,
  3. Christina Pappa1,
  4. Kianoush Zarrindej2,
  5. Joshua Rencher3,
  6. Sarah Louise Smyth1,
  7. Negin Sadeghi1,
  8. Alisha Sattar1,
  9. Stephen Damato1,
  10. Mostafa Abdalla4,
  11. Sean Kehoe1,
  12. Susan Addley5 and
  13. Hooman Soleymani Majd1
  1. 1Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  2. 2Buckinghamshire NHS Foundation Trust, Bucks, UK
  3. 3Royal Berkshire NHS Foundation Trust, Reading, UK
  4. 4Gynaecology—Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  5. 5University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK


Introduction/Background Although grade is a well-recognised prognostic factor for endometrioid endometrial cancer, in more studies grade I (G1EEC) and grade II (G2EEC) endometrioid endometrial carcinomas are combined and compared together with grade III (G3EEC) tumours. The aim of our study is to investigate separately the outcomes of grade II endometrioid endometrial adenocarcinomas and investigate whether the differentiation between G1EEC and G2EEC is clinically useful.

Methodology We retrospectively reviewed the files of patients treated with primary staging surgery for endometrioid endometrial cancer in Churchill Cancer Centre – Oxford University Hospitals NHS Foundation trust between 2010 and 2020.

Results Out of the 523 patients endometrioid endometrial cancer treated with primary surgery, 189 (36.14%) were G2EEC. Patients with G2EEC had comparable 5-years disease-free survival rates (91.6% vs. 93.2%, p=0.44), but worse 5-year cancer specific survival (93.3% vs. 98.5%, p<0.01) compared to patients with G1 EC. On the other hand, G2 EC has favourable prognosis compared to G3 EG both in terms of disease-free survival (91.6 vs. 83.8%, p=0.04) and cancer specific survival (93.3% vs. 78.5%, p<0.01). Multivariable Cox analysis of the main clinicopathological features of endometrioid endometrial cancer (stage, grade and LVSI) showed that only stage is independent risk factor for recurrence and both grade and stage are independent risk factors for cancer specific mortality.

Conclusion Although grade does not seem to affect recurrence of endometrioid endometrial cancer independently, cancer specific survival of G2ECC is significantly different from both G1EEC and G3ECC. Therefore, grading system should continue to differentiate G1EEC and G2EEC for better prognosis interpretation.

Disclosures Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.